Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Here you can browse the complete list of projects on CDAS whose requests for data/biospecimens were approved.

Data-Only Studies
Biospecimen Studies
Name Principal Investigator Institution Study Date Approved Project ID
Effects of In-Plane Spatial Resolution on Computer-Aided Diagnosis Features of Small Pulmonary Nodules David Gierada Washington University NLST Sep 3, 2009 200909-0010
Prospective assessment of thyroid cancer risk and exposure to persistent polyhalogenated aromatic hydrocarbons Briseis Kilfoy DCEG - Other PLCO Aug 21, 2009 2009-0518
Participant Tracking and Tracing in the PLCO and NLST/LSS Trials Pamela Marcus NCI, DCP, BRG PLCO Aug 13, 2009 2009-0159
Serum Melatonin and Subsequent Risk of Prostate Cancer Ann Hsing NCI, DCEG, HREB PLCO Aug 3, 2009 2008-0256
Risk factors for hepatocellular carcinoma in the United States Katherine McGlynn NCI, DCEG, HREB PLCO Jul 23, 2009 2009-0154
A prospective investigation of the relationship between use of non-steroidal anti-inflammatory drugs (NSAIDs) and risk of head and neck cancers (HNC) and malignant melanomas (MM) Amanda Black NCI, DCEG, EBP PLCO Jul 23, 2009 2009-0035
Development of a Pancreatic Cancer Risk Prediction Model Martin Tammemagi Brock University / Henry Ford Health System PLCO Jul 15, 2009 2009-0095
Risk of an Abnormal Suspicious False Positive Screening Exam for Ovarian Cancer in the PLCO Cancer Screening Trial. Sarah Nyante NCI, DCEG, HREB PLCO Jul 10, 2009 2009-0059
Diet, underlying diseases, reproductive factors and CLL/SLL Huei-Ting Tsai NCI, DCEG, GEB PLCO Jun 26, 2009 2009-0106
Participant Tracking and Tracing in the PLCO and NLST/LSS Trials Pamela Marcus National Cancer Institute NLST Jun 22, 2009 200906-0040
Phase III validation using PLCO specimens of a consensus panel of ovarian cancer biomarkers developed by SPORE/EDRN investigators: Study 4: Validation using PLCO serial specimens of PLCO Ovarian Cance Nicole Urban Fred Hutchinson Cancer Research Center PLCO Jun 19, 2009 2009-0504
Prospective evaluation of IGF and IL-6 dysregulation and multiple myeloma Mark Purdue NCI, DCEG, OEEB PLCO Jun 17, 2009 2009-0506
PLCO Participant Survey Shannon Pretzel University of Colorado Health Science Center PLCO May 28, 2009 2009-0116
Nomogram predicting the risk bladder cancer and high-grade bladder cancer Andrew Stephenson Cleveland Clinic PLCO May 26, 2009 2009-0075
Cancer Recurrence after Diagnosis of Clinically Localized Prostate Cancer Sarah Daughterty NCI, DCEG, OEEB PLCO May 26, 2009 2009-0063
Determinants of Menopausal Hormone Therapy Use in Women in the PLCO Study Bruce Kessel Pacific Health Research Institute (Hawaii) PLCO May 26, 2009 2009-0062
Factors Associated with the Timing of Follow-up After an Abnormal Cancer Screening Beth Waitzfelder Pacific Health Research Institute (Hawaii) PLCO Apr 30, 2009 2009-0023
Cohort-Based GWAS of Glioma Preetha Rajaraman NCI, DCEG, REB PLCO Apr 27, 2009 2008-0253
Detailed Analysis of Contamination and Compliance in Prostate PLCO Paul Pinsky NCI, DCP, EDRG PLCO Apr 23, 2009 2009-0076